|Dr. William Garrett Nichols M.D., MS||Chief Medical Officer||493.88k||N/A||1969|
|Mr. Michael A. Sherman||CEO, Pres & Director||N/A||N/A||1966|
|Mr. Michael T. Andriole||Chief Bus. Officer & CFO||N/A||N/A||1973|
|Mr. David Jakeman||Exec. Director of Fin. & Accounting and Principal Accounting Officer||N/A||N/A||1977|
|Dr. Roy W. Ware Ph.D., MBA||Chief Manufacturing & Technology Officer||N/A||N/A||N/A|
Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients. It is also developing CMX521, a nucleoside for the treatment of norovirus; and CMX157, a nucleoside analog for the treatment of HIV and hepatitis B virus infection. Chimerix, Inc. has license agreements with ContraVir Pharmaceuticals for the development and commercialization of CMX157 for various antiviral indications; Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; and Cantex Pharmaceuticals, Inc. for the development and commercialization of CX-01, a heparin derivative that is used in the treatment of acute myeloid leukemia and other serious diseases. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.
Chimerix, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 7. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 8; Compensation: 9.